Infectious diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …
New β-lactam–β-lactamase inhibitor combinations
D Yahav, CG Giske, A Grāmatniece… - Clinical microbiology …, 2020 - Am Soc Microbiol
The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …
Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem …
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …
Considerations and caveats in combating ESKAPE pathogens against nosocomial infections
YX Ma, CY Wang, YY Li, J Li, QQ Wan… - Advanced …, 2020 - Wiley Online Library
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter …
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter …
[HTML][HTML] Resistance to ceftazidime–avibactam and underlying mechanisms
Y Wang, J Wang, R Wang, Y Cai - Journal of global antimicrobial resistance, 2020 - Elsevier
Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …
inhibitor combination. Although the combination has been available clinically for only a few …
New perspectives on antimicrobial agents: cefiderocol
Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …
collaborative efforts between national and international organizations and the …
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach …
The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …
Resistance to novel β-lactam–β-lactamase inhibitor combinations: the “price of progress”
KM Papp-Wallace, AR Mack, MA Taracila… - Infectious Disease …, 2020 - id.theclinics.com
As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …
antimicrobials in the United States, representing more than 65% of injected antibiotic …
Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance
The emergence of bacterial resistance has motivated researchers to discover new
antibacterial agents. Nowadays, fluoroquinolones keep their status as one of the essential …
antibacterial agents. Nowadays, fluoroquinolones keep their status as one of the essential …
Treatment of infections by OXA-48-producing Enterobacteriaceae
Carbapenemase-producing Enterobacteriaceae (CPE) contribute significantly to the global
public health threat of antimicrobial resistance. OXA-48 and its variants are unique …
public health threat of antimicrobial resistance. OXA-48 and its variants are unique …